VentaProst in Subjects With COVID-19 Requiring Mechanical Ventilation

Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of VentaProst (Inhaled Epoprostenol Delivered Via Dedicated Delivery System) in Subjects With COVID-19 Requiring Mechanical Ventilation

The purpose of this study is to investigate whether inhaled epoprostenol given via a breath actuated delivery system will help improve oxygen levels and treatment outcomes in patients with COVID-19 who are on mechanical ventilation.

This study will evaluate the potential therapeutic benefit of VentaProst in treating patients with COVID-19 at risk for respiratory and/ or cardiac/circulatory failure. This is a double-blind, placebo controlled study of VentaProst in 10 confirmed COVID-19 patients compared to 10- COVID-19 placebo patients to assess the efficacy and safety of VentaProst given over 10 days at varying doses.

Inclusion Criteria:

• Confirmed COVID-19 positive by RT-PCR test
• Patients who require invasive mechanical ventilation.
• Consent or professional consent obtained

Exclusion Criteria:

• Patients on ECMO support.
• Patients receiving another inhalation research medication or inhaled nitric oxide.
• Not expected to survive for 48 hours.
• Allergy to Epoprostenol and its diluent